Health Care & Life Sciences » Biotechnology | Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc. | Ownership

Companies that own Regeneron Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Capital Research & Management Co. (World Investors)
6,062,272
5.71%
1,363,384
0.35%
06/30/2018
The Vanguard Group, Inc.
5,557,750
5.24%
76,347
0.07%
06/30/2018
BlackRock Fund Advisors
4,455,405
4.2%
-143,851
0.09%
06/30/2018
Wellington Management Co. LLP
4,378,479
4.13%
56,011
0.33%
06/30/2018
Fidelity Management & Research Co.
4,146,443
3.91%
-908,951
0.17%
06/30/2018
Loomis, Sayles & Co. LP
3,305,142
3.11%
485,387
2.5%
06/30/2018
SSgA Funds Management, Inc.
3,240,402
3.05%
-59,113
0.1%
06/30/2018
Harris Associates LP
3,148,677
2.97%
1,448,644
1.08%
06/30/2018
Sands Capital Management LLC
2,305,811
2.17%
-98,276
2.39%
06/30/2018
Henderson Global Investors Ltd.
1,802,740
1.7%
203,306
0.32%
06/30/2018

About Regeneron Pharmaceuticals

View Profile
Address
777 Old Saw Mill River Road
Tarrytown New York 10591
United States
Employees -
Website http://www.regeneron.com
Updated 07/08/2019
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.